Login to Your Account

Curis Goes Above 'Erivedge' With $30M, Licensing Deal

By Randy Osborne
Staff Writer

Thursday, November 29, 2012

Pulling down a $30 million loan against Erivedge royalties and spending $9.5 million to license a Phase II-ready apoptosis promoter from Genentech Inc. – its partner for the skin cancer product – gives Curis Inc. more financial runway, as well as worldwide rights to another promising oncology candidate.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription